Juan A. Leal, Ph. D.

**** ** ***** ***

Minneapolis, MN 55403

acxvuh@r.postjobfree.com

415-***-**** (c)

Summary of Experience:

More than twenty years working in the health care field, primarily in the pharmaceutical and biotechnology industry. Experience in Preclinical Pharmacology, Translational Medicine, Regulatory Affairs, Clinical Project Management, Clinical Operations, Clinical Development, and Business Development. Strong background in pharmacology, clinical development, regulatory affairs and clinical project management. I have participated in 18 IND submissions, 10 open INDs, 3 NDAs and 3 BLAs. I have closely work with Business Development on drug expansion and new indications (life cycle management). I also have extensive experience in leadership and managerial roles, managing budgets and contracts, competitive intelligence, and working in a cross-functional team environment. Formal training in Project Management and extensive supervisory experience (20+ direct reports).

Fluent in English and Spanish. Able to verbally communicate in Portuguese

Areas of Expertise:

Clinical:

Writer and reviewer of clinical protocols, investigator brochures, and inform consent forms

Design biomarkers strategy of clinical studies

Clinical Team member of phase 1-3 trials in Oncology

Clinical team member of global phase 2-3 in Metabolic Diseases

Site visit for selection of clinical sites

Site visit for selection of clinical research labs

Site initiation visit

Member of the weekly teleconference with study PIs to discuss new issues, related to the clinical trial, i.e. safety, efficacy, enrollment rate, etc.

Coordination of sample collections for safety, PK and biomarkers (domestic and global studies)

Prospective and retrospective multi-analysis of samples collected from global phase 2 or 3 studies

Data analysis and data review for presentations

Regulatory:

Well-versed on overall regulatory requirements on drug development

Training on SOP, IACUC, IRB, GCP, GLP, and ICH regulations

Team member of several pre-IND and IND meetings with the FDA

Participant to Pre-IND and IND meetings with the FDA

Participated in additional correspondence and meetings with FDA related to specific events associated with the clinical studies

Writer of pre-IND and IND submissions to the FDA

Writer of IRB submissions

Project Management:

Project manager of several clinical (also preclinical and translational) programs

Trained in Clinical Project Management

Trained in Project Management

Well-versed with Microsoft Project

Managed time lines, budget and deliverables of preclinical and clinical biomarker validation studies performed by collaborators or CRLs.

Managed budget, contracts, scope of works, contract negotiations and deliverables with CROs and CRLs to perform the assay development, sample processing and bioanalysis of clinical samples

Business Development:

Extensive work interaction with Clinical Operations, Medical Affairs and Business Development in clinical trials optimization, drug treatment expansions and development of new indications for an approved drug.

Oral presentations to potential partners of Translational Medicine rational and strategy of drugs in clinical development

Oral presentations to KOLs of the clinical development rational and strategy of the drug candidates

Member of in-licensing evaluation team (AMGEN)

Member of the out-licensing team

Led collaborations with academics and KOLs

Member of the competitive intelligence groups

Extensive network with peers in the pharmaceutical, biotech and CRO industry, as well as in academic, government, and other nonprofit research and development institutions

Professional Experience:

04/2013 – Present: Consultant Biopharmacology

Biopharmacology Consultant, LLC

Minneapolis, MN

Consultant on late stage preclinical development, translational medicine, regulatory affairs and clinical biomarkers strategy to academic institutions and biotech companies. Consultant on drug development strategy for Small Business Innovation Research (SBIR) grant submissions

Consultant on drug development strategy for Clinical and Translational Science Award (CTSA) grant submissions

Consultant on pre-clinical requirements for an IND submission, including preclinical non-GLP and GLP studies, study design, clinical protocol and clinical operational aspects.

Consultant on regulatory aspects on clinical development i.e. IND submission, clinical protocol, clinical development, biomarkers strategy, IRB submissions, etc.

Project Management support to design the optimal strategy to move forward an effective drug development process with limited resources.

Provided webinar training in clinical research and translational medicine

03/2011 – 04/2013 : Director, Predictive Medicine

Clinical Sciences

Translational Medicine Therapeutic Area

Regeneron Pharmaceuticals

Tarrytown, New York

Member of the Clinical Development Team of five antibody drug therapy programs, three in oncology, one in ophthalmology, and one in metabolic diseases. Led the design, implementation and evaluation of the clinical biomarkers strategy to these clinical programs as secondary endpoints, from biological rational to operational aspects related to collection, processing and analysis of the samples.

Project Leader of an ad-hoc team to design a companion diagnostic, IVD strategy to work in parallel with the drug development.

Medical Affairs’ team member of Alirocumab. Main role was to design and perform prospective and retrospective bioanalytical studies to further understand the drug’s mechanism of action, based on the analysis of new lipoproteins and other cardiovascular biomarkers in serum of patients enrolled on the clinical studies.

Medical Affairs team member of Eylea. Responsible to evaluate molecular (protein and/or DNA) markers to identify potential biomarkers as predictor’s of responders vs. non-responders to drug treatment

07/2009 – 03/2011: Director, Pharmacology & Biomarkers Core

Institute for Therapeutic Discovery and Development

Department of Medicinal Chemistry

College of Pharmacy

University of Minnesota

Minneapolis, Minnesota

Led the development of in vitro and in vivo pharmacology expertise for lead optimization and identification of potential drug candidates from projects initiated at the Institute, in collaboration with other groups from the University of Minnesota, or external academic institutions

Provided project management and pharmacology evaluation and recommendations to proposal submitted to the NCI’s Chemical Biology Consortium (CBC). The institute is one of the 14 members of the Chemical Biology Consortium initiative created by the NCI.

Designed and executed in vitro and ex vivo assays to support lead optimization efforts

Member of the Minnelide team, currently in clinical development

Chair of Small Business Innovation Research (SBIR) Phase 1 and 2 Contract proposals on anticancer agents. Division of Extramural Activities, NCI.

Reviewer Small Business Innovation Research (SBIR) Phase 2 Bridge [with Commercialization] award of proposals on anticancer agents. Division of Extramural Activities, NCI.

Reviewer Regulatory Science Grants, Division of Extramural Activities, NCI

08/2007 – 07/2009: Scientific Director

Center for Translational Medicine

Academic Health Center

University of Minnesota

Minneapolis, Minnesota

Led the implementation of a strategy and logistic about drug development activities within the University of Minnesota. Set up and managed a Translational Medicine group to move research studies toward pre-IND studies, with safety and efficacy data collected in animal models. Led the integration of basic research, pharmacology and clinical research groups and directed the pre-clinical, regulatory and clinical development activities performed by members of these groups.

Project leader and project manager of the preclinical drug development of 3 programs.

Member of the pre-IND and IND teams of Minnelide (currently in phase 1 studies).

Member of the pre-IND team, co-author of the pre-IND document submitted to the FDA and to the face to face meeting with the Agency of Tamyasin (has not moved to phase 1 yet).

03/2005 – 03/2007: Senior Director,

Head of Translational Medicine Department

Clinical Development

Exelixis Inc.

South San Francisco, California

Member of the Development Management Team, led by Executive Vice-President of Development. Members included the heads of Clinical Development, Regulatory, Translational Medicine, Pharmacokinetics and Drug Metabolism, Toxicology, Process Development, and Project Management.

Clinical Project Manager of 3 programs. Involved in the clinical development of all (8) small molecules, oncology drug candidates that reached clinical development stage

One of these 8 drug candidates has been approved for treatment of cancer, Carbozantinib

06/2000 – 03/2005: Research Scientist V / Associate Director

Cancer Pharmacology

Department of Cancer Biology

Amgen, Inc.,

Thousand Oaks, California

Newly formed group. Led the set-up of in vitro, ex-vivo, and in vivo models of efficacy, PK/PD relationship, and therapeutic index of novel anticancer drugs (small molecules, antibodies [naked and conjugated], peptibodies and proteins). Directed the development and validation of several new preclinical xenograft models of efficacy, angiogenesis and migration (metastasis), used to test the safety and efficacy of the lead compounds.

From a translational point of view, led several studies directed to identify biomarkers of efficacy to guide the evaluation of drug efficacy during the phase 1 clinical trials, including vascular imaging of the tumor.

Formal training in project management and Project Manager of 4 drug development programs.

Member of the Medical Affairs team of Denosumab. Led preclinical studies on a new indication in breast and prostate cancer bone metastasis models.

Member of the Medical Affairs team of Trebananib. Involved in the design and execution of preclinical models to test drug’s efficacy in age-related macular degeneration (AMD) and inflammation

08/1995 – 06/2000: Group Leader

Dept of Chemotherapeutics

Cancer Research Division

Abbott Laboratories,

Abbott Park, Illinois

Newly formed group. Led the set-up of in vitro, ex-vivo, and in vivo models of efficacy, PK/PD relationship, and therapeutic index of novel anticancer drugs (small molecules and peptides). Directed the development and validation of several new preclinical xenograft models of efficacy, angiogenesis and migration (metastasis), which were used to test the safety and efficacy of several lead compounds for the selection of the drug candidates. Author of Pharmacology section of 3 INDs. Regular speaker in project teams and with upper management of the preclinical development of lead compounds and rational selection of a drug candidate

06/1990 – 08/1995: Research/Senior Research Scientist,

Endocrinologist

LHRH project, Department of General Pharmacology

Drug Design and Delivery Division

Abbott Laboratories, Abbott Park, Illinois

Newly formed group. Led the setup of in vivo models of efficacy, PK/PD relationship, and therapeutic index of novel anti-prostate cancer drugs (peptides and peptidomimetics). Led the in vivo evaluation of all the lead LHRH antagonists and also the 3rd generation LHRH agonist (Lupron 3-Month).

Member of the Medical Affairs of Hytrin team. Performed preclinical studies that demonstrate efficacy in urinary blockade due to enlarged prostate models. Author of multiple scientific reports and co-author of the pharmacology section of 2 INDs. Member of the Medical Affairs team that perform preclinical studies to demonstrate Hytrin efficacy in BPH rat models

Postdoctoral Researcher in Tumor Biology

The Women's Research Institute

University of Kansas School of Medicine-Wichita

Wichita, Kansas

Postdoctoral Researcher in Endocrinology of Reproduction

The Jones Institute for Reproductive Medicine

Eastern Virginia Medical School,

Norfolk, Virginia

Three Faculty positions: Instructor to Assistant Professor

Universidad Católica, Santiago, Chile

Universidad de Santiago, Santiago, Chile

Universidad de Chile, Santiago, Chile

EDUCATION:

Completed 40/80 credits in MBA program

Kellstadt School of Business

DePaul University

Chicago, Illinois

Ph.D., Physiology and Endocrinology

Catholic University

Santiago, Chile

Licentiate in Biology (MS Equivalent)

University of Chile

Santiago, Chile

LANGUAGES:

Fluent in Spanish (native language)

Fluent in English

Proficient in Portuguese

MEMBERSHIP TO SCIENTIFIC SOCIETIES

American Association for Cancer Research (AACR)

American Society of Clinical Oncology (ASCO)

Drug Information Association (DIA)

Life Science Alley of Minnesota

BioBusiness Alliance of Minnesota

Former membership:

Federation of American Societies of Experimental Biology (FASEB)

American Association of Immunologists (AAI)

American Society of Gene Therapy (ASGT)

Endocrine Society

INVITED LECTURES:

Numerous invited conference chairmanships

Numerous invited lecturers at conferences

NCI REVIEW PANEL OF SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM

Chair and reviewer Phase 1 and 2 Contract Awards

Reviewer Phase 2 Bridge [with commercialization] Contract Awards

NCI REVIEWER OF GRANT APPLICATIONS

Regulatory Science Grants

SUMMARY OF PUBLICATIONS AND REGULATORY SUBMISSIONS:

Author or co-author of 60+ Abstracts presented at scientific meetings

Author or co-author of 30+ full publications

Have participated in 18 IND submissions,

3 NDAs (Lupron 3-month, Uro-Hytrin and Carbozantinib)

3 BLAs (Panitunumab, Denosumab, and Alirocumab).

Co-author of numerous scientific reports in support of IND filings

Author of pharmacology section for four INDs

Reviewer of five full IND submissions

REGULATORY: IND, NDA and BLA SUBMISSIONS:

Abbott Laboratories:

Author of numerous scientific reports to support the IND submission of 5 drug candidates: ABT-100, ABT-510, ABT-518, ABT-526, and ABT-770.

Co-author of Pharmacology section of the IND submission of 2 drug candidates: ABT-510 and ABT-526.

Author of numerous scientific reports to support the IND filing of 2 drugs candidates, in collaboration with TAP pharmaceuticals: A-75998, A-84861

Co-author of Pharmacology section of the IND submission of 2 drug candidates: A-75998 and A-84861

Author of scientific reports to update an open IND and NDA submission for Lupron 3-months in collaboration with TAP pharmaceuticals. Now is an FDA-approved drug.

Author of scientific reports to update an open IND and NDA submission for Uro-Hytrin. Now is an FDA-approved drug.

Amgen:

Author of multiples scientific reports to update an open IND and BLA of Panitunumab. Now is an FDA-approved drug.

Author of several scientific reports to update an open IND and BLA of Denosumab. Now is an FDA-approved drug.

Author of multiples scientific reports to update an open IND of Epratuzumab, a drug currently in clinical development by Immunomedics

Author of multiples scientific reports to support the IND filing for 2 new drugs, AMG-706, and AMG-386, currently in phase 3 clinical trials.

IND team member of AMG386

Author of Pharmacology section of Pre-IND and IND of AMG-386

Co-author of Pharmacology section and investigator’s brochure of two INDs

Exelixis:

Member of IND adjudication Team.

Participated in 5 IND submissions: XL184, an FDA-approved drug, (Carbozantinib); XL820, currently in phase 2, XL228, currently in phase 1; XL281, currently in phase 1 (in collaboration with BMS); and XL518, currently in phase 1

Co-author and reviewer of multiple submissions to the Agency, including the initiation of 12 phase 2 clinical studies

University of Minnesota:

Member of the IND submission team of Minnelide project at the University of Minnesota

Co-author of pre-IND draft that was submitted to the FDA.

Member of the IND submission team of the antiangiogenesis project at the University of Minnesota

Member of the IND submission team of Tamyasin, at VitalMedix

Co-author of pre-IND draft submitted to the FDA

Team member of the pre-IND meeting

Regeneron Pharmaceuticals:

Member of the IND submission team and the clinical development team of REGN1400, currently in phase 1

Member of the clinical team of REGN421, currently in phase 1

Member of the clinical team of REGN910, currently in phase 1b.

Member of the clinical team of REGN727, now an approved drug (Alirocumab)

SUMMARY OF CLINICAL PROJECT MANAGEMENT EXPERIENCE

Formal Training on Project Management in Late Preclinical and Clinical Project Management

AMGEN: In house training by external Project Management Trainers, offered to employees interested in becoming Project Managers as well as senior scientists that were assigned to be Project Leaders. Training was focused on Drug Development Projects, from Late Preclinical to Phase 3, global studies. Training also involved learning plus extensive practice of Microsoft Project, as the main tool to set up and track the progress and milestones of projects.

Role of Project Manager and/or Project Leader in several Drug Development Programs.

Abbott Labs: Project Leader of 3 Late Preclinical Stage Programs. I led the in vivo studies to select a drug candidate and the optimization of the dose and frequency of the drug administration. Then, the additional steps required to file an IND, i.e. safety, PKDM and PD studies. They all were Oncology drugs and they had a successful IND application. With these drugs in Clinical Trials, a Clinical Project Leader was assigned a Clinical Project Manager for these programs, but I remained a member of the Clinical Development team, as Preclinical Project Leader representative.

Amgen: In addition of receiving formal training on Project Management and Clinical Project Management, I was the project manager of 4 drug development programs, 2 in Oncology and 2 in Inflammation diseases. They were from Late Preclinical to IND and then for phase 1 safety studies. Last year at Amgen was exclusively as Project Manager, supporting the Inflammation projects.

Exelixis: Clinical Project Manager of 3 programs, mainly phase 1 and 2. Works closely with Regulatory Affairs, Clinical research and Clinical Operations to manage all the aspects of Clinical development. Also managed several research collaborations with KOLs on discovery of new indications of drugs in clinical trials.

University of Minnesota: Project Leader and Project Manager of the Late Preclinical development of 2 oncology and 1 metabolic disease programs toward an IND submission. One of the Oncology programs was out-licensed between Pre-IND and IND and it is now in Phase 1 clinical trials.

Regeneron: Member of the Clinical Development team of 3 Oncology, 1 Ophthalmology and 1 Metabolic Disease programs. Although I did not have a “Project Manager” designation, I was responsible for the management of all the aspects related to biological samples collection from patients enrolled in the clinical trials, to evaluate drug’s efficacy and drug’s safety. That role involved the design and implementation of clinical samples collection, as well as the management of sample processing, storage, and posterior bioanalysis. I also had to manage all aspects related to the selection of the Central Labs, or an academic institutions, that processed and performed bioanalysis of the samples, i.e. site visit, QA, design scope of works, negotiation on cost and time line of deliverables.

PUBLICATIONS

Patents Applications

Co-author of five patent applications: Two at Abbott Laboratories, two at Amgen Inc. and one at the University of Minnesota

Publications:

Barros C., Leal J. (1980) In vitro fertilization technique and application to study gamete interaction. Arch. Andrology 5:61-62.

Barros C., Leal J. (1982) In vitro fertilization and its use to study gamete interaction. In: In vitro fertilization and embryo transfer. E. Hafez and K. Semm (Eds). pp. 37-43, MTP Press Lim, London.

Simon J.A., Leal J., Hodgen G.D. (1987) Skin and serum pharmacokinetics of percutaneous estradiol absorption in postmenopausal women and non-human primates. In: Osteoporosis 1987. C Christiansen (Ed). pp. 11- 22, Norhaven A/S, Viborg, Denmark.

De la Lastra M., Leal J. (1988) Gonadotropin-releasing hormone (GnRH) inhibition of luteinizing hormone-induced ovulation in proestrous hypophysectomized rats. Life Sci 42:421-429.

Leal J., Williams R.F., Danforth D.R., Gordon K., Hodgen G.D. (1988). Prolonged duration of gonadotropin inhibition by a third generation GnRH antagonist. J Clin Endocrinol Metab 67:1325-1327.

Leal J., Chillik C., Itskoritz J., Won Hahn D., McGuire J., Danforth D.R., Williams R.J., Hodgen G.D. (1989) First, second and third generation GnRH antagonists: Primate studies on comparative potency with diminished histamine release. In: Proceeding of Journees Gynecolendocrinologiques du Dr. A. Netter, pp. 77-85, Paris, France.

Leal J., Cifuentes M.E., Ramirez S., De la Lastra M. (1989) Hypothalamic peptide inhibitor of LH secretion in rats. Relationship with a GnRH fragment. In: Neuroendocrine Regulation in Fertility Control. V. Singh, K. Muralidhar (Eds), NEHU Publications, pp 41-50, Shillong, India.

De La Lastra, M., Leal, J. Hypothalamic factor inhibitor of LH secretion. Relationship with fragment 1-5 of gonadotropin releasing hormone. Archivos de Biologia y Medicina Experimentales 22(1): 53-60.

Leal, J.A., Gordon, K., Williams, R.F. Danforth, D.R., Roh, S., Hodgen, G.D. (1989) Probing Studies on multiple dose effects of antide (Nal-Lys) GnRH antagonist in ovariectomized monkeys. Contraception 40:623-633.

Leal J.A., May, J.V. and Keel, B.A. (1990) Human alpha fetoprotein enhances epidermal growth factor proliferative activity upon porcine granulosa cell proliferation in monolayer culture. Endocrinology 126:669-671.

Danforth, D.R., Gordon, K., Leal, J.A., Williams, R.F., Hodgen, G.D. (1990). Extended presence of Antide (Nal-Lys GnRH antagonist) in circulation. Prolonged duration of gonadotropin inhibition may derive from antide binding to serum proteins. J Clin Endocrinol and Metab 70: 554- 556.

Simon, J.A., Leal, J., Hodgen, G.D. (1990). Percutaneous Absorption of Estradiol in ovariectomized Rhesus monkeys: Skin and serum pharmacokinetics. Fertility and Sterility 53: 561-565.

Keel, B.A., Harms, R.L., Leal, J.A., Cho, S. (1990). Characterization of human alpha fetoprotein charge microheterogeneity during fetal development. Molec Reprod Develop 27:281-287.

Hodgen, G.D., Kenisberg, D., Chillik, C., Danforth, D., Leal, J., Gordon, K., Scott, R., Williams, R. (1990) GnRH Antagonists: New development and for indications in reproductive medicine. In Proceeding of the VI World Congress on In vitro Fertilization and Alternate Assisted Reproduction, Jerusalem, Israel. pp 213- 220, Plenum Press, New York.

Leal J.A. and Keel, B.A. (1991) A simple two step purification of human and monkey alpha fetoprotein from amniotic fluid and serum. J Med Primatol 20: 35-41.

Leal J.A., Eddy K.B., Keel, B.A. (1991) Chromatofocusing profile of purified human alpha fetoprotein and albumin differs from crude samples. Effect of protein concentration on the elution of the sample. Anal Biochem 192: 411-418.

Danforth D.R., Williams R.F., Gordon K., Leal J.A., Hodgen, G.D. (1991) Inhibition of the pituitary gonadotropin secretion by the GnRH antagonist Antide: II. Development of an in vivo bioassay for characterization of pharmacokinetics and pharmacodynamics of Antide in circulation. Endocrinology 128: 2041-2044.

Leal J.A., Gangrade, B.K., Kiser, J.L., May, J.V., Keel, B.A. (1991) Human mammary tumor cell proliferation. Primary role of platelet-derived growth factor and possible synergism with alpha fetoprotein. Steroids 56: 247-251.

Leal, J., Gordon, K., Danforth, D., Williams, R., Hodgen G.D. (1991) Antide: a third generation GnRH antagonist with minimal histamine release (review). Drugs of the Future 16: 529-537.

Bush, E.N., Nguyen, A.T., Diaz, G.J., Love, S.K, Mikusa, J.P., Cybulski, V.A., Carlson, R. P., Leal, J.A., Haviv, F., Fitzpatrick, T.D., Nichols, C.J., Swenson, R.E., Mort, N., Johnson, E.S., Dodge, Knittle, J., Greer, J. (1993) Effects of A-75998 and other antagonists of gonadotropin-releasing hormone (GnRH) in castrate male rats. Endocrine J 1: 291-297.

Leal, J.A., Bush, E.N., Holst, M.R., Cybulski, V.A., Nguyen, A.T., Rhutasel, N.S., Diaz, G.J., Haviv, F., Fitzpatrick, T.D., Nichols, C.J., Swenson, R.E., Mort, N., Carlson, R.P., Dodge, P.W., Knittle, J., Greer, J. (1994) A-75998 and other GnRH antagonists supress testosterone in male beagle dogs. A comparison of single injection, multiple injection and infusion administration. Endocrine 2: 921-927.

Haviv, F., Fitzpatrick, T.D., Nichols, C.J., Swenson, R.E., Mort, N.A., Bush, E.N., Diaz, G.J., Nguyen, A.T., Love, S.K., Mikusa, J., Leal, J.A., Cybulski, V., Nellans, N., Hoffman, D.J., Dodge, P.W., Johnson, E., Knittle, J., Greer, J. (1994) The physicochemical properties and the biological activities of A-75998: An antagonist of gonadotropin releasing hormone. In: GnRH Analogs, Gonadotropins and Gonadal Peptides. P. Bouchard, A. Caraty, H.J.T. Coeling Bennink, S.N. Pavlou (Eds). London, Parthenon Publishing Group, pp 303-309.

Gu, W., Tahir, S.K., Wang, Y., Zhang, H., Sajeev, P., Cherian, S.P., O’Connor, S., Leal, J.A., Rosenberg, S.H., Ng, S-C (1999). Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur J Cancer 35: 1394-1401.

O’Connor, SJ., Barr, KJ., Wang, L., Sorensen, BK., Tasker, AS., Sham, H., Ng, SC., Cohen, J., Devine, E., Cherian, S., Saeed, B., Zhang, HC., Lee, JY., Warner, R., Tahir, S., Kovar, P., Ewing, P., Alder, J., Mitten, M., Leal, J., Marsh, K., Bauch, J., Hoffman, D.J., Sebti, S.M., Rosenberg, SH. (2000) Second –generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy. J Med Chem 42: 3701-3710.

Lynch, C.N., Wang, Y.C., Lund, J.K., Chen, Y.W., Leal, J.A, Wiley, S.R.. (1999) TWEAK induces angiogenesis and proliferation of endothelial cells. J. Biol Chem 274: 8455-8459.

Tahir, S.K., Gu, W., Zhang, H., Leal, J.A., Lee, J.Y., Kovar, P., Saeed, B., Cherian, S.P., Devine, E., Cohen, J., Warner, R., Wang, Y., Stout, D., Arendsen, D., Rosenberg, S.H., Ng, S-C. (2000). Inhibition of Farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analog. Eur J Cancer 36: 1161-1170.

Zhang, JC., Claffey, K., Sakthivel, R., Darzynkiewicz, Z., Shaw, D.E., Leal, J., Wang, YC., Lu, FM., McCrae, KR. (2000) Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB Journal 14: 2589-2600.

Oliner, J., Min, H., Leal, J., Yu, D., Rao, S., You, E., Tang, X., Kim, H., Meyer, S., Han, SJ, Hawkins, N., Rosenfeld, R., Davy, E., Graham, K., Jacobsen, R., Stevenson, S., Ho, J., Chen, Q., Hartmann, T., Michaels, M., Kelley, M., Li, L., Sitney, K., Martin, F., Sun, JR., Zhang, N., Lu, J., Estrada, J., Kumar, R., Coxon, A., Radisnky, R., Kaufman, S., Pretorius, J., Scully, S., Cattley, R., Payton, M., Coats, S., Nguyen, L., Desilva, B., Ndifor, A., Hayward, I., Boone, T., Kendall, R. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cells 6: 507-516.

Haviv, F., Bradley, M., Kalvin, D., Schneider, A., Davidson, D., Majest, S., McKay, Laura, Haskell, C., Bell, R., Nguyen, B., Marsh, K., Surben, B., Uchic, J., Ferrero, J., Wang, Y-C., Leal, J., Record, R., Hohhe, J., Badylak, S., Lesniewski, R., Henkin, J. (2005) Thrombospondin-1 mimetic peptide inhibitor of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem., 48 (8) 2838-2846, 2005.

Miller, R., Jones, J., Tomestsko, M., Armstrong, A., Zhang, N., Leal, J. et al (2005). Antitumor efficacy of the RANK ligand inhibitor OPG-Fc in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases model. J. Bone & Mineral Res, 20(Suppl 1), S117

Payton, M., Chung, G., Yakowec, P., Wong, A., Powers, D., Xiong, L., Zhang, N., Leal, J., Bush, T., Santora, V., Askew, B., Tasker, A., Radinsky, R., Kendall, R., Coats, S. (2006) Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Research 66: 4299-4308, 2006.

Coxon, A., Bready, J., Min, H., Kaufman, S., Leal, J., Yu, D., Lee, TA., Sun, JR., Estrada, J., Bolon, B., McCabe, J., Wang, L., Caenepeel, S., Hughes, P., Cordover, D., Kim, H., Han, SJ., Michaels, M., Hsu, E., Shimamoto, G., Cattley, R., Hurh, E., Nguyen, L., Wang, G., Ndifor, A., Hayward, I., Falcon, B., McDonald, D., Li, L., Boone, T., Kendall, R., Radisnky, R., Oliner, J. (2010) Context-Dependent role of Angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: Implications for AMG 386, an Angiopoietin-1/2-neutralizing peptibody. Molec Cancer Ther 9: 2641-2651.

Contact this candidate